Checkpoint Therapeutics’ (CKPT) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research report report published on Monday,Benzinga reports. HC Wainwright currently has a $20.00 price objective on the stock.

Checkpoint Therapeutics Price Performance

Shares of NASDAQ:CKPT opened at $3.57 on Monday. The company’s fifty day moving average price is $3.55 and its 200-day moving average price is $2.69. The firm has a market capitalization of $174.33 million, a price-to-earnings ratio of -1.94 and a beta of 1.34. Checkpoint Therapeutics has a one year low of $1.38 and a one year high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). As a group, equities research analysts expect that Checkpoint Therapeutics will post -0.91 EPS for the current year.

Institutional Trading of Checkpoint Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CKPT. Virtu Financial LLC bought a new stake in Checkpoint Therapeutics in the third quarter worth $30,000. XTX Topco Ltd bought a new position in Checkpoint Therapeutics during the 2nd quarter worth approximately $34,000. Gladstone Institutional Advisory LLC lifted its position in Checkpoint Therapeutics by 141.4% in the third quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock valued at $78,000 after purchasing an additional 20,500 shares during the last quarter. Magnus Financial Group LLC boosted its stake in shares of Checkpoint Therapeutics by 12.9% during the third quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock valued at $78,000 after purchasing an additional 4,000 shares during the period. Finally, Choreo LLC grew its holdings in shares of Checkpoint Therapeutics by 12.2% in the second quarter. Choreo LLC now owns 65,002 shares of the company’s stock worth $133,000 after purchasing an additional 7,080 shares during the last quarter. Hedge funds and other institutional investors own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.